Justin Guinney, VP Computational Oncology
Justin Guinney is the Vice President of the Computational Oncology group at Sage Bionetworks. His group contains specialists from multiple domains, including molecular biology, computer science, and oncology, and focuses on the development of computational models for optimizing patient diagnosis, prognosis, and treatment in cancer. Dr. Guinney is an expert at large-scale analysis of genomic data, and works regularly with clinicians to link these models to complex cancer phenotypes. Prior to joining Sage Bionetworks, he co-founded and managed a software company called FiveSight Technologies, now part of Intalio Corp. Dr. Guinney received a BA from the University of Pennsylvania in History, a BS from the University of Illinois, Urbana-Champaign in Electrical Engineering, and a PhD from Duke University in Computational Biology and Bioinformatics.
The Computational Oncology team has a diverse portfolio of projects spanning both cancer specific initiatives and more general biomedical informatics. Our two largest initiatives are providing data and scientific coordination to the NCI-funded Cancer Systems Biology Consortium (CSBC) and the Human Tumor Atlas Network (HTAN). Our role as DCC in each of these are to support the ingress, curation, and dissemination of research artifacts (e.g. data, models, publications) to research communities. We have developed – and continue to optimize – processes and tools to support these activities at an increasing scale. Other data and scientific coordination include (i) Project GENIE – a large data sharing network of academic cancer centers performing clinical sequencing of tumors (ii) iAtlas – an immune-oncology platform for aggregating and studying immunophenotypes in cancer (iii) Clinical Data to Health – an NCATs supported initiative to improve biomedical informatics support across CTSAs (iv) Neurofibramatosis (NF) Open Science Framework – a network of NF investigators committed to data and insight sharing and supported through several NF foundations. The CompOnc team is also committed to original research, and we are leading several research projects focused on different disease indications including colorectal cancer, AML, and CML.